Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Stock Has Average Target Price of $62.83

Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) have earned an average rating of “Hold” from the seven ratings firms that are currently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, two have assigned a hold rating and four have given a buy rating to the company. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $62.83.

Several brokerages recently weighed in on SUPN. Cantor Fitzgerald upped their target price on shares of Supernus Pharmaceuticals from $63.00 to $67.00 and gave the stock an “overweight” rating in a research note on Thursday, July 9th. Wall Street Zen cut shares of Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, August 8th. Weiss Ratings restated a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a research note on Monday. Finally, Zacks Research lowered Supernus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Friday, September 4th.

Supernus Pharmaceuticals Price Performance

Shares of Supernus Pharmaceuticals stock opened at $43.29 on Friday. The stock has a market capitalization of $2.52 billion, a price-to-earnings ratio of -22.55, a price-to-earnings-growth ratio of 0.81 and a beta of 0.56. The business has a 50-day moving average of $45.17 and a 200 day moving average of $47.31. Supernus Pharmaceuticals has a 12 month low of $40.51 and a 12 month high of $59.68.

Supernus Pharmaceuticals (NASDAQ:SUPN) last issued its quarterly earnings results on Monday, August 3rd. The specialty pharmaceutical company reported ($1.01) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.42 by ($1.43). Supernus Pharmaceuticals had a positive return on equity of 11.13% and a negative net margin of 13.23%.The business had revenue of $219.06 million for the quarter, compared to analyst estimates of $205.31 million. During the same period in the prior year, the company posted $0.40 EPS. The firm’s revenue for the quarter was up 32.4% compared to the same quarter last year. Equities research analysts anticipate that Supernus Pharmaceuticals will post 1.97 earnings per share for the current year.

Institutional Investors Weigh In On Supernus Pharmaceuticals

Several large investors have recently bought and sold shares of SUPN. Mystic Asset Management Inc. purchased a new stake in shares of Supernus Pharmaceuticals in the 2nd quarter valued at approximately $1,181,000. Bank of America Corp DE lifted its position in shares of Supernus Pharmaceuticals by 37.2% during the 1st quarter. Bank of America Corp DE now owns 714,226 shares of the specialty pharmaceutical company’s stock worth $36,918,000 after purchasing an additional 193,479 shares during the last quarter. BlackRock Inc. acquired a new position in shares of Supernus Pharmaceuticals during the second quarter worth $434,871,000. Allworth Financial LP purchased a new position in Supernus Pharmaceuticals in the second quarter valued at $2,357,000. Finally, Great Lakes Advisors LLC purchased a new position in Supernus Pharmaceuticals in the second quarter valued at $1,386,000.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing and commercializing treatments for central nervous system (CNS) disorders. The company’s portfolio addresses conditions including epilepsy, migraine and attention-deficit/hyperactivity disorder (ADHD), with an emphasis on extended-release and other drug-delivery technologies.

Supernus markets Oxtellar XR (oxcarbazepine extended-release) for the treatment of partial-onset seizures and Trokendi XR (topiramate extended-release) for certain epilepsy indications and the prevention of migraine headaches.